Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Gubra A/S Director's Dealing 2024

Mar 4, 2024

6302_rns_2024-03-04_c3a909c1-b6b4-4505-ae12-16e8505e6e2c.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Regulatory press release

04 March 2024 21:41:00 CET

gubra

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A /S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name Monika Lessl
2. Reason for the notification
a) Position/status Board member in Gubra
b) Initial notification/ Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Gubra A/S
b) LEI 254900T17RRFZONO6W53
4.1 Details of the transaction(s):
a) Description of the financial instrument, type of instrument. Identification code Shares
ISIN DK0062266474
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 215.33 889

Gubra

Hørsholm Kongevej 11B

2970 Hørsholm


Regulatory press release

04 March 2024 21:41:00 CET

gubra

| d) | Aggregated information
— Aggregated volume
— Price | Average price per share:
DKK 215.33
Total number of shares:
889
Total price: DKK 191,427.66 |
| --- | --- | --- |
| e) | Date of the transaction | 4 March 2024 |
| f) | Place of the transaction | NASDAQ Copenhagen A/S |

Contacts at Gubra

Media: Sofia Pitt Boserup, [email protected], +45 4188 9586

Investors: Kristian Borbos, [email protected], +45 3080 8035

About Gubra

Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See www.gubra.dk for more information.

This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-04 21:41 CET.

Gubra

Hørsholm Kongevej 11B

2970 Hørsholm